Loading…

Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa

To describe associations of high-risk human papillomavirus (HR-HPV) with high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA). Prospective cohort of WLHIV attending HIV outpatient clinics and treatment centres. Recruitment...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2017-03, Vol.12 (3), p.e0174117-e0174117
Main Authors: Kelly, Helen A, Ngou, Jean, Chikandiwa, Admire, Sawadogo, Bernard, Gilham, Clare, Omar, Tanvier, Lompo, Olga, Doutre, Sylviane, Meda, Nicolas, Weiss, Helen A, Delany-Moretlwe, Sinead, Segondy, Michel, Mayaud, Philippe
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c593t-db274134873399da16373db8e314cd112ecd299a764b57ac793cd6c308d6dca93
cites cdi_FETCH-LOGICAL-c593t-db274134873399da16373db8e314cd112ecd299a764b57ac793cd6c308d6dca93
container_end_page e0174117
container_issue 3
container_start_page e0174117
container_title PloS one
container_volume 12
creator Kelly, Helen A
Ngou, Jean
Chikandiwa, Admire
Sawadogo, Bernard
Gilham, Clare
Omar, Tanvier
Lompo, Olga
Doutre, Sylviane
Meda, Nicolas
Weiss, Helen A
Delany-Moretlwe, Sinead
Segondy, Michel
Mayaud, Philippe
description To describe associations of high-risk human papillomavirus (HR-HPV) with high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA). Prospective cohort of WLHIV attending HIV outpatient clinics and treatment centres. Recruitment was stratified by ART status. Cervical HPV genotyping using INNO-LiPA and histological assessment of 4-quadrant cervical biopsies at enrolment and 16 months later. Among women with CIN2+ at baseline, the prevalence of any HR-HPV genotypes included in the bi/quadrivalent (HPV16/18) or nonavalent (HPV16/18/31/35/45/52/58) HPV vaccines ranged from 37% to 90%. HPV58 was most strongly associated with CIN2+ (aOR = 5.40, 95%CI: 2.77-10.53). At 16-months follow-up, persistence of any HR-HPV was strongly associated with incident CIN2+ (aOR = 7.90, 95%CI: 3.11-20.07), as was persistence of HPV16/18 (aOR = 5.25, 95%CI: 2.14-12.91) and the additional HR types in the nonavalent vaccine (aOR = 3.23, 95%CI: 1.23-8.54). HR-HPV persistence is very common among African WLHIV and is linked to incident CIN2+. HPV vaccines could prevent between 37-90% of CIN2+ among African WLHIV.
doi_str_mv 10.1371/journal.pone.0174117
format article
fullrecord <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_1880542250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b4d31feff0ae491096b63cd904362c35</doaj_id><sourcerecordid>1888963989</sourcerecordid><originalsourceid>FETCH-LOGICAL-c593t-db274134873399da16373db8e314cd112ecd299a764b57ac793cd6c308d6dca93</originalsourceid><addsrcrecordid>eNqNUlFv0zAQjhCIjcE_QGCJl1aoxY4TJ35BKhWjlSqYBOzVuthO4pLawU467QfxP0nWbtomHniydffdd3fffVH0muA5oRn5sHW9t9DMW2f1HJMsISR7Ep0STuMZizF9eu9_Er0IYYtxSnPGnkcncU4p5YydRn8WIThpoDPOBuRKtOp3YNEFtKZp3A72xvcBTVYXl1NUaeu661YHdGW6GtWmqmeVB6WR1H5vJDTIatc2EAygyXL9NX4_RcYiQNLVzncj_ZXbaYsasze2OtCs1pcj6FPvfxkL6ByCQ2AV-u76Ibso_UD8MnpWQhP0q-N7Fv08__xjuZptvn1ZLxebmUw57WaqiAcZaJJnw3ZcAWE0o6rINSWJVITEWqqYc8hYUqQZyIxTqZikOFdMSeD0LHp74G0bF8RR4SBInuM0ieMUD4j1AaEcbEXrzQ78tXBgxE3A-UqA74xstCgSRUmpyxKDTjjBnBVs6MdxQlksaTpwfTx264udVlLbzkPzgPRhxppaVG4vUsqGQ47DTA8E9aOy1WIjxthgi4wyzvZkwE6Ozbz73evQiZ0JUjcNDDfrb3bMOaM85_8DJTGjCR4nePcI-m_RkgNKeheC1-XdsASL0cy3VWI0sziaeSh7c1-fu6Jb99K_V3_xdw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1880542250</pqid></control><display><type>article</type><title>Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Kelly, Helen A ; Ngou, Jean ; Chikandiwa, Admire ; Sawadogo, Bernard ; Gilham, Clare ; Omar, Tanvier ; Lompo, Olga ; Doutre, Sylviane ; Meda, Nicolas ; Weiss, Helen A ; Delany-Moretlwe, Sinead ; Segondy, Michel ; Mayaud, Philippe</creator><contributor>Charpentier, Charlotte</contributor><creatorcontrib>Kelly, Helen A ; Ngou, Jean ; Chikandiwa, Admire ; Sawadogo, Bernard ; Gilham, Clare ; Omar, Tanvier ; Lompo, Olga ; Doutre, Sylviane ; Meda, Nicolas ; Weiss, Helen A ; Delany-Moretlwe, Sinead ; Segondy, Michel ; Mayaud, Philippe ; HARP Study Group ; for the HARP Study Group ; Charpentier, Charlotte</creatorcontrib><description>To describe associations of high-risk human papillomavirus (HR-HPV) with high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA). Prospective cohort of WLHIV attending HIV outpatient clinics and treatment centres. Recruitment was stratified by ART status. Cervical HPV genotyping using INNO-LiPA and histological assessment of 4-quadrant cervical biopsies at enrolment and 16 months later. Among women with CIN2+ at baseline, the prevalence of any HR-HPV genotypes included in the bi/quadrivalent (HPV16/18) or nonavalent (HPV16/18/31/35/45/52/58) HPV vaccines ranged from 37% to 90%. HPV58 was most strongly associated with CIN2+ (aOR = 5.40, 95%CI: 2.77-10.53). At 16-months follow-up, persistence of any HR-HPV was strongly associated with incident CIN2+ (aOR = 7.90, 95%CI: 3.11-20.07), as was persistence of HPV16/18 (aOR = 5.25, 95%CI: 2.14-12.91) and the additional HR types in the nonavalent vaccine (aOR = 3.23, 95%CI: 1.23-8.54). HR-HPV persistence is very common among African WLHIV and is linked to incident CIN2+. HPV vaccines could prevent between 37-90% of CIN2+ among African WLHIV.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0174117</identifier><identifier>PMID: 28333966</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Biology and Life Sciences ; Biopsy ; Birth control ; Burkina Faso - epidemiology ; Cancer ; Cervical cancer ; Cervix Uteri - pathology ; Cervix Uteri - virology ; Chlamydia ; Drug therapy ; Epidemiology ; Female ; Genotype ; Genotypes ; Genotyping ; Gynecology and obstetrics ; HIV ; HIV Infections - complications ; HIV Infections - epidemiology ; Hospitals ; Human health and pathology ; Human immunodeficiency virus ; Human papillomavirus ; Humans ; Hygiene ; Infections ; Infectious diseases ; Laboratories ; Lentivirus ; Life Sciences ; Medical screening ; Medicine ; Medicine and Health Sciences ; Papillomaviridae ; Papillomaviridae - genetics ; Papillomavirus Infections - complications ; Papillomavirus Infections - virology ; Papillomavirus Vaccines - therapeutic use ; Population ; Prevalence ; Prospective Studies ; Reproductive health ; Research and Analysis Methods ; Retroviridae ; Santé publique et épidémiologie ; South Africa - epidemiology ; Systematic review ; Trichomonas vaginalis ; Uterine Cervical Neoplasms - epidemiology ; Uterine Cervical Neoplasms - etiology ; Uterine Cervical Neoplasms - pathology ; Vaccines ; Womens health</subject><ispartof>PloS one, 2017-03, Vol.12 (3), p.e0174117-e0174117</ispartof><rights>2017 Kelly et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2017 Kelly et al 2017 Kelly et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c593t-db274134873399da16373db8e314cd112ecd299a764b57ac793cd6c308d6dca93</citedby><cites>FETCH-LOGICAL-c593t-db274134873399da16373db8e314cd112ecd299a764b57ac793cd6c308d6dca93</cites><orcidid>0000-0001-7636-7616 ; 0000-0003-0376-1019 ; 0000-0003-4954-2225 ; 0000-0003-3736-5663 ; 0000-0001-5547-3807</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1880542250/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1880542250?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28333966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01773696$$DView record in HAL$$Hfree_for_read</backlink></links><search><contributor>Charpentier, Charlotte</contributor><creatorcontrib>Kelly, Helen A</creatorcontrib><creatorcontrib>Ngou, Jean</creatorcontrib><creatorcontrib>Chikandiwa, Admire</creatorcontrib><creatorcontrib>Sawadogo, Bernard</creatorcontrib><creatorcontrib>Gilham, Clare</creatorcontrib><creatorcontrib>Omar, Tanvier</creatorcontrib><creatorcontrib>Lompo, Olga</creatorcontrib><creatorcontrib>Doutre, Sylviane</creatorcontrib><creatorcontrib>Meda, Nicolas</creatorcontrib><creatorcontrib>Weiss, Helen A</creatorcontrib><creatorcontrib>Delany-Moretlwe, Sinead</creatorcontrib><creatorcontrib>Segondy, Michel</creatorcontrib><creatorcontrib>Mayaud, Philippe</creatorcontrib><creatorcontrib>HARP Study Group</creatorcontrib><creatorcontrib>for the HARP Study Group</creatorcontrib><title>Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>To describe associations of high-risk human papillomavirus (HR-HPV) with high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA). Prospective cohort of WLHIV attending HIV outpatient clinics and treatment centres. Recruitment was stratified by ART status. Cervical HPV genotyping using INNO-LiPA and histological assessment of 4-quadrant cervical biopsies at enrolment and 16 months later. Among women with CIN2+ at baseline, the prevalence of any HR-HPV genotypes included in the bi/quadrivalent (HPV16/18) or nonavalent (HPV16/18/31/35/45/52/58) HPV vaccines ranged from 37% to 90%. HPV58 was most strongly associated with CIN2+ (aOR = 5.40, 95%CI: 2.77-10.53). At 16-months follow-up, persistence of any HR-HPV was strongly associated with incident CIN2+ (aOR = 7.90, 95%CI: 3.11-20.07), as was persistence of HPV16/18 (aOR = 5.25, 95%CI: 2.14-12.91) and the additional HR types in the nonavalent vaccine (aOR = 3.23, 95%CI: 1.23-8.54). HR-HPV persistence is very common among African WLHIV and is linked to incident CIN2+. HPV vaccines could prevent between 37-90% of CIN2+ among African WLHIV.</description><subject>Adult</subject><subject>Biology and Life Sciences</subject><subject>Biopsy</subject><subject>Birth control</subject><subject>Burkina Faso - epidemiology</subject><subject>Cancer</subject><subject>Cervical cancer</subject><subject>Cervix Uteri - pathology</subject><subject>Cervix Uteri - virology</subject><subject>Chlamydia</subject><subject>Drug therapy</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Genotype</subject><subject>Genotypes</subject><subject>Genotyping</subject><subject>Gynecology and obstetrics</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - epidemiology</subject><subject>Hospitals</subject><subject>Human health and pathology</subject><subject>Human immunodeficiency virus</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Hygiene</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Laboratories</subject><subject>Lentivirus</subject><subject>Life Sciences</subject><subject>Medical screening</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Papillomaviridae</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomavirus Infections - complications</subject><subject>Papillomavirus Infections - virology</subject><subject>Papillomavirus Vaccines - therapeutic use</subject><subject>Population</subject><subject>Prevalence</subject><subject>Prospective Studies</subject><subject>Reproductive health</subject><subject>Research and Analysis Methods</subject><subject>Retroviridae</subject><subject>Santé publique et épidémiologie</subject><subject>South Africa - epidemiology</subject><subject>Systematic review</subject><subject>Trichomonas vaginalis</subject><subject>Uterine Cervical Neoplasms - epidemiology</subject><subject>Uterine Cervical Neoplasms - etiology</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Vaccines</subject><subject>Womens health</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNUlFv0zAQjhCIjcE_QGCJl1aoxY4TJ35BKhWjlSqYBOzVuthO4pLawU467QfxP0nWbtomHniydffdd3fffVH0muA5oRn5sHW9t9DMW2f1HJMsISR7Ep0STuMZizF9eu9_Er0IYYtxSnPGnkcncU4p5YydRn8WIThpoDPOBuRKtOp3YNEFtKZp3A72xvcBTVYXl1NUaeu661YHdGW6GtWmqmeVB6WR1H5vJDTIatc2EAygyXL9NX4_RcYiQNLVzncj_ZXbaYsasze2OtCs1pcj6FPvfxkL6ByCQ2AV-u76Ibso_UD8MnpWQhP0q-N7Fv08__xjuZptvn1ZLxebmUw57WaqiAcZaJJnw3ZcAWE0o6rINSWJVITEWqqYc8hYUqQZyIxTqZikOFdMSeD0LHp74G0bF8RR4SBInuM0ieMUD4j1AaEcbEXrzQ78tXBgxE3A-UqA74xstCgSRUmpyxKDTjjBnBVs6MdxQlksaTpwfTx264udVlLbzkPzgPRhxppaVG4vUsqGQ47DTA8E9aOy1WIjxthgi4wyzvZkwE6Ozbz73evQiZ0JUjcNDDfrb3bMOaM85_8DJTGjCR4nePcI-m_RkgNKeheC1-XdsASL0cy3VWI0sziaeSh7c1-fu6Jb99K_V3_xdw</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Kelly, Helen A</creator><creator>Ngou, Jean</creator><creator>Chikandiwa, Admire</creator><creator>Sawadogo, Bernard</creator><creator>Gilham, Clare</creator><creator>Omar, Tanvier</creator><creator>Lompo, Olga</creator><creator>Doutre, Sylviane</creator><creator>Meda, Nicolas</creator><creator>Weiss, Helen A</creator><creator>Delany-Moretlwe, Sinead</creator><creator>Segondy, Michel</creator><creator>Mayaud, Philippe</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-7636-7616</orcidid><orcidid>https://orcid.org/0000-0003-0376-1019</orcidid><orcidid>https://orcid.org/0000-0003-4954-2225</orcidid><orcidid>https://orcid.org/0000-0003-3736-5663</orcidid><orcidid>https://orcid.org/0000-0001-5547-3807</orcidid></search><sort><creationdate>20170301</creationdate><title>Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa</title><author>Kelly, Helen A ; Ngou, Jean ; Chikandiwa, Admire ; Sawadogo, Bernard ; Gilham, Clare ; Omar, Tanvier ; Lompo, Olga ; Doutre, Sylviane ; Meda, Nicolas ; Weiss, Helen A ; Delany-Moretlwe, Sinead ; Segondy, Michel ; Mayaud, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c593t-db274134873399da16373db8e314cd112ecd299a764b57ac793cd6c308d6dca93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Biology and Life Sciences</topic><topic>Biopsy</topic><topic>Birth control</topic><topic>Burkina Faso - epidemiology</topic><topic>Cancer</topic><topic>Cervical cancer</topic><topic>Cervix Uteri - pathology</topic><topic>Cervix Uteri - virology</topic><topic>Chlamydia</topic><topic>Drug therapy</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Genotype</topic><topic>Genotypes</topic><topic>Genotyping</topic><topic>Gynecology and obstetrics</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - epidemiology</topic><topic>Hospitals</topic><topic>Human health and pathology</topic><topic>Human immunodeficiency virus</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Hygiene</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Laboratories</topic><topic>Lentivirus</topic><topic>Life Sciences</topic><topic>Medical screening</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Papillomaviridae</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomavirus Infections - complications</topic><topic>Papillomavirus Infections - virology</topic><topic>Papillomavirus Vaccines - therapeutic use</topic><topic>Population</topic><topic>Prevalence</topic><topic>Prospective Studies</topic><topic>Reproductive health</topic><topic>Research and Analysis Methods</topic><topic>Retroviridae</topic><topic>Santé publique et épidémiologie</topic><topic>South Africa - epidemiology</topic><topic>Systematic review</topic><topic>Trichomonas vaginalis</topic><topic>Uterine Cervical Neoplasms - epidemiology</topic><topic>Uterine Cervical Neoplasms - etiology</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Vaccines</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kelly, Helen A</creatorcontrib><creatorcontrib>Ngou, Jean</creatorcontrib><creatorcontrib>Chikandiwa, Admire</creatorcontrib><creatorcontrib>Sawadogo, Bernard</creatorcontrib><creatorcontrib>Gilham, Clare</creatorcontrib><creatorcontrib>Omar, Tanvier</creatorcontrib><creatorcontrib>Lompo, Olga</creatorcontrib><creatorcontrib>Doutre, Sylviane</creatorcontrib><creatorcontrib>Meda, Nicolas</creatorcontrib><creatorcontrib>Weiss, Helen A</creatorcontrib><creatorcontrib>Delany-Moretlwe, Sinead</creatorcontrib><creatorcontrib>Segondy, Michel</creatorcontrib><creatorcontrib>Mayaud, Philippe</creatorcontrib><creatorcontrib>HARP Study Group</creatorcontrib><creatorcontrib>for the HARP Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kelly, Helen A</au><au>Ngou, Jean</au><au>Chikandiwa, Admire</au><au>Sawadogo, Bernard</au><au>Gilham, Clare</au><au>Omar, Tanvier</au><au>Lompo, Olga</au><au>Doutre, Sylviane</au><au>Meda, Nicolas</au><au>Weiss, Helen A</au><au>Delany-Moretlwe, Sinead</au><au>Segondy, Michel</au><au>Mayaud, Philippe</au><au>Charpentier, Charlotte</au><aucorp>HARP Study Group</aucorp><aucorp>for the HARP Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>12</volume><issue>3</issue><spage>e0174117</spage><epage>e0174117</epage><pages>e0174117-e0174117</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>To describe associations of high-risk human papillomavirus (HR-HPV) with high-grade cervical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA). Prospective cohort of WLHIV attending HIV outpatient clinics and treatment centres. Recruitment was stratified by ART status. Cervical HPV genotyping using INNO-LiPA and histological assessment of 4-quadrant cervical biopsies at enrolment and 16 months later. Among women with CIN2+ at baseline, the prevalence of any HR-HPV genotypes included in the bi/quadrivalent (HPV16/18) or nonavalent (HPV16/18/31/35/45/52/58) HPV vaccines ranged from 37% to 90%. HPV58 was most strongly associated with CIN2+ (aOR = 5.40, 95%CI: 2.77-10.53). At 16-months follow-up, persistence of any HR-HPV was strongly associated with incident CIN2+ (aOR = 7.90, 95%CI: 3.11-20.07), as was persistence of HPV16/18 (aOR = 5.25, 95%CI: 2.14-12.91) and the additional HR types in the nonavalent vaccine (aOR = 3.23, 95%CI: 1.23-8.54). HR-HPV persistence is very common among African WLHIV and is linked to incident CIN2+. HPV vaccines could prevent between 37-90% of CIN2+ among African WLHIV.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>28333966</pmid><doi>10.1371/journal.pone.0174117</doi><orcidid>https://orcid.org/0000-0001-7636-7616</orcidid><orcidid>https://orcid.org/0000-0003-0376-1019</orcidid><orcidid>https://orcid.org/0000-0003-4954-2225</orcidid><orcidid>https://orcid.org/0000-0003-3736-5663</orcidid><orcidid>https://orcid.org/0000-0001-5547-3807</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2017-03, Vol.12 (3), p.e0174117-e0174117
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1880542250
source Publicly Available Content (ProQuest); PubMed Central
subjects Adult
Biology and Life Sciences
Biopsy
Birth control
Burkina Faso - epidemiology
Cancer
Cervical cancer
Cervix Uteri - pathology
Cervix Uteri - virology
Chlamydia
Drug therapy
Epidemiology
Female
Genotype
Genotypes
Genotyping
Gynecology and obstetrics
HIV
HIV Infections - complications
HIV Infections - epidemiology
Hospitals
Human health and pathology
Human immunodeficiency virus
Human papillomavirus
Humans
Hygiene
Infections
Infectious diseases
Laboratories
Lentivirus
Life Sciences
Medical screening
Medicine
Medicine and Health Sciences
Papillomaviridae
Papillomaviridae - genetics
Papillomavirus Infections - complications
Papillomavirus Infections - virology
Papillomavirus Vaccines - therapeutic use
Population
Prevalence
Prospective Studies
Reproductive health
Research and Analysis Methods
Retroviridae
Santé publique et épidémiologie
South Africa - epidemiology
Systematic review
Trichomonas vaginalis
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - etiology
Uterine Cervical Neoplasms - pathology
Vaccines
Womens health
title Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T14%3A52%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Associations%20of%20Human%20Papillomavirus%20(HPV)%20genotypes%20with%20high-grade%20cervical%20neoplasia%20(CIN2+)%20in%20a%20cohort%20of%20women%20living%20with%20HIV%20in%20Burkina%20Faso%20and%20South%20Africa&rft.jtitle=PloS%20one&rft.au=Kelly,%20Helen%20A&rft.aucorp=HARP%20Study%20Group&rft.date=2017-03-01&rft.volume=12&rft.issue=3&rft.spage=e0174117&rft.epage=e0174117&rft.pages=e0174117-e0174117&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0174117&rft_dat=%3Cproquest_plos_%3E1888963989%3C/proquest_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c593t-db274134873399da16373db8e314cd112ecd299a764b57ac793cd6c308d6dca93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1880542250&rft_id=info:pmid/28333966&rfr_iscdi=true